Evolus, Inc.

Annual Trend FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Net loss ($46.9m) ($90.0m) ($163.0m) ($46.8m) ($74.4m) ($61.7m) ($50.4m) ($51.6m)
Net Income ($74.4m)
($61.7m) +17.10%
($50.4m) +18.26%
($51.6m) -2.42%
($34.3m) +33.52%
Depreciation and amortization $9k $4.1m $7.0m $5.6m $3.7m $5.1m $5.3m $7.5m $10.2m
Amortization of operating lease right-of-use assets $873k $654k $692k $775k $734k $723k $1.2m
Amortization of debt discount and issuance costs $863k $2.2m $2.7m $941k $1.1m $1.1m $1.1m $1.3m
Amortization Of Securities $272k $0 $0
Depreciation Amortization Depletion $4.5m $5.9m $6.0m $8.7m $10.2m
Deferred income taxes $65k ($15.1m) $25k $15k ($18k) $5k ($21k) $21k ($583k)
Deferred Tax ($18k) $5k ($21k) $21k ($583k)
Stock-based compensation $7.0m $9.5m $10.6m $9.6m $10.8m $16.5m $22.3m $20.7m $21.0m
Change In Working Capital ($34.3m) ($5.9m) ($6.6m) ($22.5m) ($16.3m)
Accounts receivable $0 ($11.0m) ($1.1m) ($5.6m) ($9.4m) ($9.5m) ($19.6m) ($11.5m) ($18.5m)
Change In Receivables ($9.4m) ($9.5m) ($19.6m) ($11.5m) ($18.5m)
Changes In Account Receivables ($9.4m) ($9.5m) ($19.6m) ($11.5m) ($18.5m)
Provision for credit losses and inventory $1.4m $2.4m $6.5m
Inventories $0 ($4.5m) $4.5m ($3.0m) ($10.7m) $4.2m $3.3m ($11.1m) ($1.8m)
Change In Inventory ($10.7m) $4.2m $3.3m ($11.1m) ($1.8m)
Accounts payable $1.3m $183k $2.3m ($787k) $968k ($1.0m) $391k $10.1m $1.2m
Capital expenditures included in accounts payable and accrued expenses $0 $87k $0 $10k $0 $43k $252k $695k ($6.5m)
Change In Payables And Accrued Expense ($19.2m) $3.0m $7.4m $3.7m $1.2m
Accrued expenses $2.7m ($2.7m) ($4.2m) $20.9m ($5.2m) $9.0m $7.0m ($6.4m) $9.0m
Accrued litigation settlement $35.0m ($15.0m) ($15.0m) ($5.0m) $0 $0
Change In Accrued Expense ($20.2m) $4.0m $7.0m ($6.4m) $9.0m
Other operating assets ($211k) ($190k) $1.5m $0 ($864k) $706k ($2.5m)
Change In Other Current Assets $4.9m ($864k) $706k ($2.5m) ($5.2m)
Change In Other Current Liabilities ($977k) ($907k) ($716k) ($758k) ($1.3m)
Net cash used in operating activities ($25.7m)
($93.4m) -263.83%
($57.9m) +38.03%
($33.4m) +42.31%
($84.9m) -154.32%
($34.0m) +59.95%
($18.0m) +47.07%
($42.3m) -134.82%
($15.4m) +63.61%
Purchases of property and equipment ($9k) ($345k) ($815k) ($393k) ($1.6m) ($473k) ($1.5m) ($3.4m) ($6.5m)
Capital Expenditure Reported ($1.3m) ($1.2m) ($3.4m) ($5.0m) ($6.5m)
Net cash used in investing activities ($9k) ($23.4m) $12.2m $4.0m ($2.9m) ($1.6m) ($4.8m) ($8.5m) ($6.5m)
Proceeds from issuance and modification of debt instruments $50.0m $0 $25.0m
Payments for debt modification fees and debt issuance costs ($46k) $0 ($2.6m)
Issuance Of Debt $0 $50.0m $0 $25.0m $10.0m
Long Term Debt Issuance $0 $50.0m $0 $25.0m $10.0m
Long Term Debt Payments $0 $0 $0 ($15k) ($16k)
Net Issuance Payments Of Debt $0 $50.0m $0 $25.0m $10.0m
Repayment Of Debt $0 $0 $0 ($15k) ($16k)
Issuance of common stock in connection with incentive equity plan ($239k) $2.5m $0 $655k $539k $224k $4.9m $1.2m $0
Issuance of common stock in connection with Symatese Europe Agreement $0 $1.5m $0 $0 $0
Common Stock Issuance $0 $0 $51.2m $0 $0
Issuance Of Capital Stock $0 $0 $51.2m $0 $0
Tax withholding paid on behalf of employees for net share settlement ($239k) $4k $65k $14k $0 ($7k) ($990k) $0
Net Other Financing Charges ($4.7m) ($5.6m) ($8.7m) ($8.8m) ($4.8m)
Net cash provided by financing activities $118.8m
$133.5m +12.38%
$38.3m -71.29%
$73.1m +90.50%
($4.1m) -105.68%
$44.6m +1176.72%
$47.4m +6.21%
$17.3m -63.43%
$5.6m -67.94%
Net increase (decrease) in cash and cash equivalents $93.2m ($7.3m) $43.7m ($92.3m) $8.9m $24.1m ($33.1m)
Cash and cash equivalents, beginning of period $93.2m $109.9m $102.6m $146.3m $53.9m $62.8m $87.0m $53.8m
Beginning Cash Position $146.3m $53.9m $62.8m $87.0m $61.7m
Effect of exchange rates on cash and cash equivalents $0 ($337k) ($90k) ($478k) $254k
Effect Of Exchange Rate Changes ($337k) ($90k) ($478k) $254k ($231k)
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Revaluation of contingent royalty obligation payable to Evolus Founders $10.5m $4.2m ($2.0m) $6.3m $5.8m $4.3m $7.2m ($6.4m)
Non-cash in-process research and development expense $0 $4.4m $0 $0
Other adjustments to operating activities $0 $36k $967k
Prepaid expenses ($254k) $1.2m ($1.8m) $2.4m ($355k)
Operating lease liabilities ($654k) ($734k) ($838k) ($977k) ($907k) ($716k) ($758k)
Additions to capitalized software $0 ($4.2m) ($2.3m) ($577k) ($1.3m) ($1.2m) ($3.4m) ($5.0m)
Payment of contingent royalty obligation to Evolus Founders $0 ($9.7m) ($1.1m) ($3.1m) ($4.2m) ($5.5m) ($7.4m) ($6.2m)
Proceeds from follow-on offering $67.7m $73.3m $0 $103.3m $0 $0 $51.2m $0
Payments for offering costs ($1.1m) ($203k) $0 ($214k) $0 $0 ($248k) $0
Payment of finance lease obligations $0 $0 ($15k)
Cash paid for interest $0 $5.2m $7.2m $138k $8.0m $12.7m $17.5m $14.8m
Cash paid for income taxes ($239k) $4k $65k $14k $76k $117k $235k $1.2m
Cash Flow From Continuing Financing Activities ($4.1m) $44.6m $47.4m $17.3m $5.6m
Cash Flow From Continuing Investing Activities ($2.9m) ($1.6m) ($4.8m) ($8.5m) ($6.5m)
Change In Account Payable $968k ($1.0m) $391k $10.1m $1.2m
Change In Cash Supplemental As Reported ($92.3m) $8.9m $24.1m ($33.1m)
Change In Payable $968k ($1.0m) $391k $10.1m $1.2m
Change In Prepaid Assets $1.2m ($1.8m) $2.4m ($355k) $380k
Changes In Cash ($92.0m) $9.0m $24.6m ($33.4m) ($16.3m)
End Cash Position $53.9m $62.8m $87.0m $53.8m $45.4m
Financing Cash Flow ($4.1m)
$44.6m +1176.72%
$47.4m +6.21%
$17.3m -63.43%
$5.6m -67.94%
Free Cash Flow ($87.9m) ($35.6m) ($22.8m) ($50.7m) ($21.9m)
Investing Cash Flow ($2.9m) ($1.6m) ($4.8m) ($8.5m) ($6.5m)
Net Investment Purchase And Sale $5.0m $0
Net PPE Purchase And Sale ($1.6m) ($473k) ($1.5m) ($3.4m) ($2.9m)
Other Non Cash Items $6.8m $9.8m $8.4m ($4.1m)
Proceeds From Stock Option Exercised $539k $231k $4.9m $1.2m $412k
Provisionand Write Offof Assets $1.6m $1.4m $2.4m $6.5m $5.7m
Purchase Of PPE $9k $345k $815k $393k ($1.6m) ($473k) ($1.5m) ($3.4m) ($6.5m)
Sale Of Investment $5.0m $0